The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2
Open accessAbstract
Receptor tyrosine kinases (RTKs) play distinct roles in multiple biological systems. Many RTKs transmit similar signals, raising questions about how specificity is achieved. One potential mechanism for RTK specificity is control of the magnitude and kinetics of activation of downstream pathways. We have found that the protein tyrosine phosphatase Shp2 regulates the strength and duration of phosphatidylinositol 3'-kinase (PI3K) activation in the epidermal growth factor (EGF) receptor signaling pathway. Shp2 mutant fibroblasts exhibit increased association of the p85 subunit of PI3K with the scaffolding adapter Gab1 compared to that for wild-type (WT) fibroblasts or Shp2 mutant cells reconstituted with WT Shp2. Far-Western analysis suggests increased phosphorylation of p85 binding sites on Gab1. Gab1-associated PI3K activity is increased and PI3K-dependent downstream signals are enhanced in Shp2 mutant cells following EGF stimulation. Analogous results are obtained in fibroblasts inducibly expressing dominant-negative Shp2. Our results suggest that, in addition to its role as a positive component of the Ras-Erk pathway, Shp2 negatively regulates EGF-dependent PI3K activation by dephosphorylating Gab1 p85 binding sites, thereby terminating a previously proposed Gab1-PI3K positive feedback loop. Activation of PI3K-dependent pathways following stimulation by other growth factors is unaffected or decreased in Shp2 mutant cells. Thus, Shp2 regulates the kinetics and magnitude of RTK signaling in a receptor-specific manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“Receptor tyrosine kinases (RTKs) play critical roles in the regulation of cell growth, motility, differentiation, and death (12, 37).”
BackgroundHunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Signaling Through Scaffold, Anchoring, and Adaptor Proteins
Pawson, T., & Scott, J. D. (1997) · Science · doi:10.1126/science.278.5346.2075 · Cited by 2,256
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Frangioni, J. V., & Neel, B. G. (1993) · Analytical Biochemistry · doi:10.1006/abio.1993.1170 · Cited by 879
Self-citationProtein tyrosine phosphatases in signal transduction
Neel, B. G., & Tonks, N. K. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80063-4 · Cited by 753
Self-citationA Grb2-associated docking protein in EGF- and insulin-receptor signalling
Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K., & Wong, A. J. (1996) · Nature · doi:10.1038/379560a0 · Cited by 677
Cited by
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Self-citationA comprehensive pathway map of epidermal growth factor receptor signaling
Oda, K., Matsuoka, Y., Funahashi, A., & Kitano, H. (2005) · Molecular Systems Biology · doi:10.1038/msb4100014 · Cited by 1,158
Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment
Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., Luo, J., Thompson, J. A., Schraven, B. L., Philips, M. R., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00050-4 · Cited by 447
Self-citationThe ‘Gab’ in signal transduction
Gu, H., & Neel, B. G. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00002-3 · Cited by 388
Self-citationThe tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
Self-citationThe molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
Dance, M., Montagner, A., Salles, J.-P., Yart, A., & Raynal, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.002 · Cited by 361
Cell‐death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques
ATALE, N., GUPTA, S., YADAV, U. C. S., & RANI, V. (2014) · Journal of Microscopy · doi:10.1111/jmi.12133 · Cited by 357
Singh, A. M., Reynolds, D., Cliff, T., Ohtsuka, S., Mattheyses, A. L., Sun, Y., Menendez, L., Kulik, M., & Dalton, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.01.014 · Cited by 356
NOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Self-citationProtein tyrosine phosphatases as potential therapeutic targets
He, R.-J., Yu, Z.-H., Zhang, R.-Y., & Zhang, Z.-Y. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.80 · Cited by 327
Angiotensin-(1-7) Counterregulates Angiotensin II Signaling in Human Endothelial Cells
Sampaio, W. O., Henrique de Castro, C., Santos, R. A. S., Schiffrin, E. L., & Touyz, R. M. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.084848 · Cited by 283
Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44972 · Cited by 282
Self-citationThe Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
Self-citationRegulation of Receptor Tyrosine Kinase Signaling by Protein Tyrosine Phosphatase-1B
Haj, F. G., Markova, B., Klaman, L. D., Bohmer, F. D., & Neel, B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210194200 · Cited by 266
Self-citationAn Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival
Yang, W., Klaman, L. D., Chen, B., Araki, T., Harada, H., Thomas, S. M., George, E. L., & Neel, B. G. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.01.002 · Cited by 263
Self-citationAdachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
“While SHP2 can negatively regulate the level of AKT signaling by dephosphorylating the p85 binding sites on GAB1 following EGF stimulation (39), there has been conflicting reports on the role of SHP2 in the activation of IGFR–IRS signaling (39–41).”
BackgroundSHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232
Araki, T., Nawa, H., & Neel, B. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306461200 · Cited by 231
Self-citationInterleukin-6 signalling: More than Jaks and STATs
Eulenfeld, R., Dittrich, A., Khouri, C., Müller, P. J., Mütze, B., Wolf, A., & Schaper, F. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.010 · Cited by 171
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
“SHP2 inhibitors are often considered as a pan-RTK inhibitor but in most cases we tested, TNO155 only inhibits the RAS– MAPKpathway downstreamofRTK signalingwithout any acute effect on the PI3K–AKT, PLCg–PKC, and JAK–STAT pathways (Fig.”
BackgroundInfluentialKolli, S., Zito, C. I., Mossink, M. H., Wiemer, E. A. C., & Bennett, A. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313955200 · Cited by 154
Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
A new mechanism for the regulation of Gab1 recruitment to the plasma membrane
Eulenfeld, R., & Schaper, F. (2009) · Journal of Cell Science · doi:10.1242/jcs.037226 · Cited by 57
Fiebelkow, J., Guendel, A., Guendel, B., Mehwald, N., Jetka, T., Komorowski, M., Waldherr, S., Schaper, F., & Dittrich, A. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00770-7 · Cited by 53
“Thus, altered MAPK activation in MEF SHP2 ΔEx3 cells [47] could indirectly contribute to the reduced robustness of STAT3 activation and Channel Capacity in SHP2 mutant cells (Fig.”
BackgroundPérez-Baena, M. J., Cordero-Pérez, F. J., Pérez-Losada, J., & Holgado-Madruga, M. (2023) · Cancers · doi:10.3390/cancers15164179 · Cited by 25
“Furthermore, SHP2 has been shown to dephosphorylate the tyrosine residues of GAB1 involved in the recruitment of p85 and Ras GTPase-activating protein (RasGAP) [61,62].”
Background
Metadata
- Authors
- Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., & Neel, B. G.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2002-06
- Volume
- 22
- Issue
- 12
- Pages
- 4062-4072
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2107546866
- Cited by
- 282
- References
- 48
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.